Co-dopa CR 100 mg+25 mg (Tablet (Controlled Release))
Unit Price: ৳ 10.00 (3 x 10: ৳ 300.00)
Strip Price: ৳ 100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Levodopa carbidopa cr tablet |
| Company | Unimed unihealth pharmaceuticals ltd |
| Also available as |
Indications
- Idiopathic Parkinson's disease
- Reduction of off-period in patients previously treated with levodopa/decarboxylase inhibitors
- Motor fluctuations
Description
- Levodopa as metabolic precursor of dopamine
- Carbidopa as dopa decarboxylase (DDC) inhibitor
- Crosses blood-brain barrier
- Conversion of levodopa to dopamine in the brain
- Reduction of peripheral metabolism of levodopa to dopamine
Dosage
- Initial substitution amount not more than 10% additional levodopa per day
- Dosing interval prolongation by 30 to 50%
- Titration based on clinical response
- Guideline for conversion from conventional Levodopa/Carbidopa tablet to Levodopa-Carbidopa prolonged-release tablet
Administration
- Discontinuation of levodopa at least eight hours before therapy
- Initial recommended dose for patients with mild to moderate disease
- Doses and dosing intervals adjustment based on therapeutic response
- Periodic clinical evaluations for maintenance
- Addition of other antiparkinson medication
Interaction
- Caution with concomitant administration of specific drugs
- Dosage adjustment of antihypertensive drug may be required
- Rare adverse reactions with concomitant use of tricyclic antidepressants
- Effects of anticholinergics on absorption and patient's response
- Decrease in bioavailability of carbidopa and/or levodopa with iron
- Therapeutic effects reduction with dopamine D2 receptor antagonists and isoniazid
- Observation for loss of therapeutic response with certain drugs
Contraindications
- Contraindicated with sympathomimetic amine
- Non-selective monoamine oxidase inhibitors contraindicated
- Discontinuation of non-selective monoamine oxidase inhibitors two weeks prior to therapy
- Known hypersensitivity to any component of the medication
- Contraindicated in patients with narrow-angle glaucoma
Side Effects
- Dyskinesia
- Nausea
- Hallucinations
- Confusion
- Dizziness
- Chorea
- Dry mouth
- Dream abnormalities
- Dystonia
- Insomnia
- Depression
- Asthenia
- Vomiting
- Anorexia
- Chest pain
- Palpitation
- Constipation
- Diarrhoea
- Dyspepsia
- Gastro-intestinal pain
- Dark saliva
- Angioedema
- Urticaria
- Pruritus
- Weight loss
- Neuroleptic malignant syndrome
- Agitation
- Anxiety
- Decreased mental acuity
- Paraesthesia
- Disorientation
- Fatigue
- Headache
- Extrapyramidal and movement disorders
- Falling
- Gait abnormalities
- Muscle cramps
- On-off phenomenon
- Increased libido
- Psychotic episodes
- Dyspnoea
- Flushing
- Alopecia
- Rash
- Dark sweat
- Blurred vision
- Dark urine
- Cardiac irregularities
- Hypertension
- Phlebitis
- Bitter taste
- Sialorrhoea
- Dysphagia
- Bruxism
- Hiccups
- Gastro-intestinal bleeding
- Flatulence
- Burning sensation of tongue
- Development of duodenal ulcer
- Leucopenia
- Haemolytic and non-haemolytic anaemia
- Thrombocytopenia
- Agranulocytosis
Pregnancy & Lactation
- Insufficient data for harmfulness evaluation in human pregnancy
- Unknown excretion of carbidopa in human milk
- Excretion of levodopa in breast milk reported in a study
- Not recommended during pregnancy and to nursing mothers
Precautions & Warnings
- Discontinuation of levodopa prior to therapy
- Possible dyskinesias occurrence requiring dosage reduction
- Not recommended for drug-induced extrapyramidal reactions or Huntingdon’s chorea treatment
- Onset of effect in patients with early morning dyskinesias may be slower
- Cardiac function monitoring in patients with severe diseases
- Caution in patients with recent myocardial infarction and residual arrhythmia
- Association with somnolence and sudden sleep onset
- Need for caution during driving or operating machines
- Dosage reduction or therapy termination may be considered
Use in Special Populations
- Safety and effectiveness not established in infants and children
- Use not recommended in patients below the age of 18
Therapeutic Class
- Antiparkinson drugs
Storage Conditions
- Store in a cool and dry place
- Protected from light
Related Brands
- Cinemet CR 200 mg+50 mg (Tablet (Controlled Release)) - aci-limited
- Syndopa CR 100 mg+25 mg (Tablet (Controlled Release)) - sun-pharmaceutical-bangladesh-ltd
- Syndopa CR 200 mg+50 mg (Tablet (Controlled Release)) - sun-pharmaceutical-bangladesh-ltd
- Co-dopa CR 200 mg+50 mg (Tablet (Controlled Release)) - unimed-unihealth-pharmaceuticals-ltd
- Cinemet CR 100 mg+25 mg (Tablet (Controlled Release)) - aci-limited